SCHEMBL7219030

SCHEMBL7219030

Nc1ccnc2[nH]c3ccccc3c12

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.68
ALK Q9UM73 2/20 0.54
ERBB2 P04626 4/20 0.53
UTS2R Q9UKP6 6/20 0.50
PTK6 Q13882 4/20 0.50
EGFR P00533 3/20 0.49
SRC P12931 1/20 0.48
ACVR1 Q04771 1/20 0.48
AURKC Q9UQB9 1/20 0.48
CA5A P35218 1/20 0.47
NCF1 P14598 1/20 0.46
GABRA1 P14867 1/20 0.45
GABRG2 P18507 1/20 0.45
GABRB3 P28472 1/20 0.45
GABRA5 P31644 1/20 0.45
GABRA3 P34903 1/20 0.45
GABRA2 P47869 1/20 0.45
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3459309 0.81 AURKA (1.00) AURKA
SCHEMBL13461148 0.79 ERBB2 (0.70) AURKAALKERBB2UTS2RPTK6
SCHEMBL16011809 0.78 ALK (0.54) AURKAALKERBB2UTS2RPTK6
SCHEMBL31240940 0.78 AURKA (0.68) AURKAALKERBB2UTS2RPTK6
SCHEMBL675631 0.78 AURKA (0.68) AURKAALKERBB2UTS2RPTK6
SCHEMBL23967951 0.78 ERBB2 (0.65) AURKAALKERBB2UTS2RPTK6
SCHEMBL17559198 0.78 ALK (0.54) AURKAALKERBB2UTS2RPTK6
SCHEMBL31662764 0.76 AURKA (0.49) AURKAALKERBB2UTS2RPTK6
SCHEMBL3473013 0.76 LIMK1 (0.59) ALKERBB2EGFRCA5AMAPT
SCHEMBL30159366 0.76 LIMK1 (0.59) ALKERBB2EGFRCA5AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6670371-B2 Antagonists of Corticotropin-Releasing Factor NEUROGEN CORPORATION 2003-12-30 US disclosed
US-20020111490-A1 Certain pyrrolopyridine derivatives: novel CRF1 specific ligands NEUROGEN CORPORATION (US) 2002-08-15 US disclosed
US-6355651-B1 AMINE SUBSTITUTED HETEROCYCLIC COMPOUNDS NEUROGEN CORPORATION 2002-03-12 US disclosed
US-6133282-A Certain pyrrolopyridine derivatives; novel CRF1 specific ligands NEUROGEN CORPORATION (US) 2000-10-17 US disclosed
WO-1998045295-A1 CERTAIN PYRROLOPYRIDINE DERIVATIVES; NOVEL CRF1 SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111490-A1 Certain pyrrolopyridine derivatives: novel CRF1 specific ligands CRHR1, CRH, CRHR2 AURKA 3950/4885ALK 737/4885ERBB2 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.